Title:
USE OF β-1 ADRENOCEPTOR ANTAGONIST FOR PREPARING COMPOSITION FOR REDUCING EPITHELIAL CELL DAMAGE INDUCED BY EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITOR AND INHIBITING CANCER CELLS
Document Type and Number:
WIPO Patent Application WO/2022/007878
Kind Code:
A1
Abstract:
A use of a β-1 adrenoceptor antagonist for preparing a composition for reducing or preventing normal epithelial cell damage induced by an epidermal growth factor receptor inhibitor and inhibiting cancer cells. The composition comprising the β-1 adrenoceptor antagonist can be administered to reduce the normal epithelial cell damage induced by the epidermal growth factor receptor inhibitor, and can be administered together with the epidermal growth factor receptor inhibitor for inhibiting cancer cells in a synergistic manner.
Inventors:
LU CHUN-WEI (CN)
SU PANG JONG-HWEI (CN)
KO YU-SHIEN (CN)
CHUNG WEN-HUNG (CN)
CHEN MEI-JUN (CN)
SU PANG JONG-HWEI (CN)
KO YU-SHIEN (CN)
CHUNG WEN-HUNG (CN)
CHEN MEI-JUN (CN)
Application Number:
PCT/CN2021/105167
Publication Date:
January 13, 2022
Filing Date:
July 08, 2021
Export Citation:
Assignee:
CHANG GUNG MEMORIAL HOSPITAL LINKOU (CN)
UNIV CHANG GUNG (CN)
UNIV CHANG GUNG (CN)
International Classes:
A61K31/165; A61K31/138; A61K31/517; A61K31/5377; A61P1/04; A61P17/00; A61P17/02; A61P27/02; A61P35/00
Foreign References:
| US20200206164A1 | 2020-07-02 | |||
| CN105263482A | 2016-01-20 | |||
| CN1402634A | 2003-03-12 | |||
| CN108743588A | 2018-11-06 | |||
| CN109414431A | 2019-03-01 | |||
| CA2880236A1 | 2014-01-30 | |||
| CN102006864A | 2011-04-06 | |||
| CN104189906A | 2014-12-10 | |||
| US4938949A | 1990-07-03 |
Other References:
HERBST, RS ET AL.: "Dermatologic side effects associated with gefitinib therapy: clinical experience and management.", CLIN LUNG CANCER, vol. 4, no. 6, 2003, pages 366 - 9
HERBST, RS ET AL.: "Dermatologic side effects associated with gefitinib therapy: clinical experience and management", CLIN LUNG CANCER, vol. 4, no. 6, 2003, pages 366 - 9
HERBST, RS ET AL.: "Dermatologic side effects associated with gefitinib therapy: clinical experience and management", CLIN LUNG CANCER, vol. 4, no. 6, 2003, pages 366 - 9
Attorney, Agent or Firm:
LIU, SHEN & ASSOCIATES (CN)
Download PDF: